Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 15;17:355–370. doi: 10.2147/COPD.S342357

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Price et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Covariate plot showing standardised mean differences (SMD) for comparison of baseline characteristics for new users of inhaled fixed dose combinations with fine particle fluticasone or extrafine particle beclometasone before and after propensity score matching.

Notes: Acute_ocs, number of acute oral steroid prescriptions; days_prior, number of days available in-patient record prior to index date; drug_group, COPD drug group classification in baseline period (No therapy, SABA/SAMA, LABA, LABA + LAMA, LAMA); ocs_maintenance, number of maintenance oral steroid prescriptions in baseline period.

Abbreviations: BMI, body mass index; CKD, chronic kidney disease; FEV1, forced expiratory volume in one second; GERD, Gastro-eosophageal reflux disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IHD, ischemic heart disease; LAMA, long acting muscarinic antagonist; LTRA, Leukotriene receptor antagonists; MRC, Medical Research Council; OCS, oral corticosteroids; PS, propensity score; SABA, short-acting beta-agonist; SAMA, short acting muscarinic antagonist; SMD, standardised mean difference.